Argus Research analyst Kristina Ruggeri upgrades Celestica (NYSE:CLS) from Hold to Buy and announces $14 price target.
Argus Research Upgrades Celestica to Buy, Announces $14 Price Target
Argus Research analyst Kristina Ruggeri upgrades Celestica (NYSE:CLS) from Hold to Buy and announces $14 price target.
Related Posts
Rite Aid Forges Path To Financial Recovery With Major Settlement: Report
Rite Aid (OTC: RADCQ) settles with lenders and DOJ, marking a crucial step toward bankruptcy resolution by April, Reuters reports. Attorney Aparna Yenamandra highlights broad stakeholder agreement, signaling progress despite remaining complexities. Junior bondholders, including Brigade Capital Management, express caution.
Incannex Submits IND Application To The U.S. FDA For IHL-42X For Obstructive Sleep Apnoea
Incannex Healthcare Limited (NASDAQ:IXHL) (ASX: IHL), (‘Incannex' or the ‘Company') a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and
Analyst Ratings for Nutrien
Nutrien (NYSE:NTR) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish…